Stay updated with breaking news from Full Year. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic device products for
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing
Exro generated revenue of $5,736,140 for the twelve months that ended December 31, 2023.The Company lifted the nondisclosure agreement with Giaffone and announced the completion of Coil DriverTM validation in Q4 2023 and acceptance of purchase order...
CULVER CITY, Calif., April 2, 2024 /PRNewswire/ -- Snail, Inc. (NASDAQ: SNAL) ("Snail" or "the Company"), a leading, global independent developer and
ANN ARBOR, MI / ACCESSWIRE / April 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic device products for